Marc Monte
Medical Oncology · Jonesboro, ARNPI 1255327763
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,486 and has fallen 98.1% since, to $28 in 2021. That places this record below the midpoint for medical oncology clinicians in AR, where the typical reported total is $1,872.
Across 137 payments — averaging $13.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$240
- Merck$181
- Daiichi Sankyo Inc.$142
- E.r. Squibb & Sons, L.L.C.$109
- AstraZeneca$108
- Eisai Inc.$95
- plus $998 from 30 others
Across 45 payments — averaging $1359.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$28K
- Bristol Myers Squibb$18K
- Amgen$11K
- Pharmacyclics LLC, An Abbvie Company$4K
- Seagen Inc.$36
What the payments were for
- Food & beverage$1,80496%
- Education$684%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 23 | $240 |
| Merck | 15 | $181 |
| Daiichi Sankyo Inc. | 4 | $142 |
| E.r. Squibb & Sons, L.L.C. | 10 | $109 |
| AstraZeneca(2 entities) | 8 | $108 |
| Eisai Inc. | 7 | $95 |
| Bayer | 6 | $86 |
| Johnson & Johnson(2 entities) | 5 | $79 |
| Bristol Myers Squibb | 5 | $75 |
| Novartis | 5 | $64 |
| Lilly USA, LLC | 4 | $56 |
| Amgen | 3 | $54 |
| Puma Biotechnology, Inc. | 3 | $47 |
| Portola Pharmaceuticals, LLC | 2 | $41 |
| AbbVie | 3 | $41 |
| Astellas Pharma US Inc | 3 | $40 |
| Foundation Medicine, Inc. | 3 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $28 |
| Rigel Pharmaceuticals, Inc. | 2 | $26 |
| Kyowa Kirin, Inc. | 2 | $26 |
| Array Biopharma Inc | 2 | $25 |
| Sanofi | 2 | $25 |
| Collegium Pharmaceutical, Inc. | 2 | $24 |
| Genentech USA, Inc. | 2 | $24 |
| AMAG Pharmaceuticals, Inc. | 2 | $22 |
| Tolmar Pharmaceuticals, Inc. | 1 | $19 |
| Clovis Oncology, Inc. | 1 | $18 |
| Exelixis Inc. | 1 | $16 |
| Dendreon Pharmaceuticals LLC | 1 | $15 |
| Seagen Inc. | 1 | $15 |
| EMD Serono, Inc. | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
| Secura Bio, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INJECTAFER$102
How this compares
$1,872 in reported general payments places this provider in the 50th percentile of 20 medical oncology providers in Arkansas.
Other medical oncology in Jonesboro
- Muthu KumaranLittle Rock$193K
- Sunilkumar KakadiaHot Springs$31K
- Cesar Gentille SanchezLittle Rock$29K
- Stephen ToothakerSearcy$19K
- Ryan KochSearcy$15K
- Zaki SammanFort Smith$9K
- Kristen SagerMena$8K
- Chen HuangHarrison$5K
- William RobertsonSearcy$4K
- Shadiqul HoqueNorth Little Rock$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.